scholarly journals Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population

2018 ◽  
Vol Volume 11 ◽  
pp. 7883-7894 ◽  
Author(s):  
Jia-Yan Ni ◽  
Shan-Shan Liu ◽  
Hong-Liang Sun ◽  
Wei-Dong Wang ◽  
Ze-Long Zhong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Meta Analysis ◽  
Asian Population ◽  
Hepatic Arterial Infusion ◽  
Barcelona Clinic Liver Cancer ◽  
Cancer Stage ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy

Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis

2019 ◽  
Vol 49 (9) ◽  
pp. 845-855
Author(s):  
Bo-wen Zhuang ◽  
Wei Li ◽  
Xiao-hua Xie ◽  
Hang-tong Hu ◽  
Ming-de Lu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Response ◽  
Meta Analysis ◽  
Hepatic Arterial Infusion ◽  
Hepatic Arterial Infusion Chemotherapy ◽  
Advanced Hepatocellular Carcinoma ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Alternative Treatment Option

Our meta-analysis showed hepatic arterial infusion chemotherapy provided better tumor response and survival benefits than Sorafenib for advanced hepatocellular carcinoma and should be recommended as an alternative treatment option.

scholarly journals Sorafenib is more effective in the treatment of TACE-refractory hepatocellular carcinoma than hepatic arterial infusion chemotherapy: a meta-analysis

2020 ◽  
Author(s):  
Shufeng Wang ◽  
Shasha Tang ◽  
Long Pan ◽  
XiuJun Cai
Keyword(s):  
Hepatocellular Carcinoma ◽  
Meta Analysis ◽  
Objective Response ◽  
Hepatic Arterial Infusion ◽  
Hepatic Arterial Infusion Chemotherapy ◽  
Arterial Infusion ◽  
Sorafenib Treatment ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Sorafenib Group

Abstract Background: Currently, several studies have compared the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in the treatment of TACE-refractory hepatocellular carcinoma (HCC), but the conclusion is inconsistent. The purpose of this meta-analysis was to compare the effectiveness of sorafenib and HAIC in patients with TACE-refractory HCC.Methods Multi-databases were searched to identify relevant studies published from inception to March 2020. The quality evaluation and data extraction were carried out for the selected articles meeting the inclusion and exclusion criteria. The data was analyzed using STATA16.Results Five studies with 583 patients were included. Although the objective response rate in the HAIC group was significantly higher than that in the sorafenib group (RR = 3.08, 95%CI [1.38, 6.87], p=0.006), the overall survival (OS) was significantly shorter than that in the patients receiving sorafenib treatment (HR = 1.69, 95% CI [1.09, 2.62], p=0.018). Progression-free survival (HR = 1.21, 95% CI [0.76, 1.92], p=0.426) and disease control rate (RR = 0.94, 95% CI [0.60, 1.48], p=0.798) were not significantly different between the two groups.Conclusion Compared with HAIC, patients with TACE- refractory HCC in the sorafenib group can obtain significantly longer OS. Sorafenib may be more suitable for the treatment of patients with TACE-refractory HCC. High-quality evidence is needed.

Hepatic arterial infusion chemotherapy versus Sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis

2020 ◽  
Author(s):  
guoqing ouyang ◽  
Guangdong Pan ◽  
Qiang Liu ◽  
Yongrong Wu ◽  
shengqiang Tan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Response Rate ◽  
Meta Analysis ◽  
Hepatic Arterial Infusion ◽  
Hepatic Arterial Infusion Chemotherapy ◽  
Cochrane Library ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Advanced Hcc ◽  
Infusion Chemotherapy

Abstract Background : Hepatocellular carcinoma (HCC) is ranked as the sixth most common solid cancer and the third leading cause of cancer-related death in the world. Sorafenib is the first line systematic treatment for patients with advanced HCC. Hepatic arterial infusion chemotherapy（HAIC）has been proved to be an effective treatment for advanced HCC. Here, we conducted a meta-analysis to compared the efficacy of HAIC versus sorafenib of advanced HCC patients with PVTT. Methods : The databases of MEDLINE (PubMed), Cochrane Library, EMBASE, and Web of Science were systematically searched for retrieving the relevant publications before 31 July 2019. The endpoint included overall survival (OS), time to progression (TTP), partial response rate (PRR), complete response rate (CRR), objective response rate (ORR), stable disease rate (SDR). Results : A total of three studies involving 214 advanced HCC patients with PVTT enrolled in this meta-analysis. HAIC significantly improved TTP (hazard ratio (HR) = 0.56, 95% CI: 0.39-0.82; P = 0.003), PRR (odds ratio (OR) = 3.31, 95% CI: 1.46-7.50; P = 0.004), ORR (OR = 3.78, 95% CI: 1.68-8.50; P = 0.001) compared to sorafenib. However, no significant difference was found in OS (HR=0.77, 95%CI: 0.56-1.06, p=0.11), CRR (OR = 2.54, 95% CI: 0.39-16.47; P = 0.33), SDR (OR = 1.48, 95% CI: 0.43-5.08; P = 0.001). Conclusions : This meta-analysis suggested that HAIC provides better TTP, PRR, ORR than sorafenib for patients of advanced HCC with PVTT. Therefore, we recommend HAIC as a potential therapy for advanced HCC patients with PVTT. However, owing to the above limitations, more high-quality studies are warranted to evaluate this finding.

scholarly journals The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Chemotherapy ◽  
2021 ◽  
Vol 66 (4) ◽  
pp. 124-133
Author(s):  
Shengzhou Li ◽  
Jiaxuan Xu ◽  
Hongya Zhang ◽  
Jiaze Hong ◽  
Yuexiu Si ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Effect ◽  
Meta Analysis ◽  
Hepatic Arterial Infusion ◽  
Hepatic Arterial Infusion Chemotherapy ◽  
Cochrane Library ◽  
Arterial Infusion ◽  
Free Survival ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy

<b><i>Background:</i></b> The main aim of this study was to investigate comprehensively the clinical effect of hepatic arterial infusion chemotherapy (HAIC) on patients suffering from hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> The following electronic databases were searched for eligible articles published from inception to July 2020: PubMed, Web of Science, Embase, and Cochrane Library. The main final indicators were overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). <b><i>Results:</i></b> A total of 26 studies entailing 4,506 cases were included for a meta-analysis. The results showed that HAIC could improve advanced HCC patients’ OS (HR, 0.49; 95% CI: 0.37–0.61) and PFS (HR, 0.52; 95% CI: 0.36–0.68). Remarkably, compared with Japan (HR, 0.58) and Korea (HR, 0.54), for the unresectable HCC patients, the HAIC group achieved higher efficacy on OS than the control group in China (HR, 0.24). The resectable HCC patients, who received HAIC adjuvant chemotherapy, exhibited favorable prognosis for OS (HR, 0.58; 95% CI: 0.27–0.88) and DFS (HR, 0.49; 95% CI: 0.31–0.68). <b><i>Conclusion:</i></b> HAIC improved long-term survival for both resectable and unresectable HCC patients in comparison with other therapies. However, the clinical effect of HAIC needs to be ascertained by large-scale well-designed studies.

Sign in / Sign up

Export Citation Format

Share Document